Left ventricular hypertrophy in COPD without hypoxemia: The elephant in the room?

Chest

Volumn 143, Issue 1, 2013, Pages 91-97

  Anderson, William J ^a   Lipworth, Brian J ^a   Rekhraj, Sushma ^a   Struthers, Allan D ^a   George, Jacob ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIAC PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HUMAN; HYPOXEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXYGEN SATURATION; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SEX RATIO; SPIROMETRY; SYSTOLIC BLOOD PRESSURE;

EID: 84871970308     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0775     Document Type: Article

References (37)

1. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. http://www.goldcopd.org/. Published 2011. Accessed July 1, 2012.
2. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956-962.
3. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1(8222):681-686.
4. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561-1566. (Pubitemid 20176696)
6. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273(20):1592-1597.
7. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32(5):1454-1459. (Pubitemid 28522409)
8. Nakashima Y, Nii T, Ikeda M, Arakawa K. Role of left ventricular regional nonuniformity in hypertensive diastolic dysfunction. J Am Coll Cardiol. 1993;22(3):790-795. (Pubitemid 23256941)
9. Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med. 1995;98(3):272-277.
10. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol. 1990;15(1):43-51. (Pubitemid 20034248)
11. Schillaci G, Pirro M, Mannarino E. Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone? Hypertension. 2007;50(5):851-853. (Pubitemid 350287525)
12. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54(6):505-512.
13. Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation. 2007;116(7):700-705. (Pubitemid 47260463)
14. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242-1248. (Pubitemid 44394895)
15. Okin PM, Devereux RB, Harris KE, et al LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147(5):311-319. (Pubitemid 351664558)
16. Kassis E. Systemic hypertension, left ventricular hypertrophy and myocardial infarction in patients with chronic obstructive lung disease. Scand J Respir Dis. 1977;58(6):324-329. (Pubitemid 8268560)
17. Lang RM, Bierig M, Devereux RB, et al Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-1463. (Pubitemid 41821197)
18. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450-458. (Pubitemid 16119719)
19. Sokolow M, Freidlander RD. The normal unipolar precordial and limb lead electrocardiogram. Am Heart J. 1949;38(5):665-687.
20. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. National Institute for Health and Clinical Excellence website. http://publications.nice.org.uk/ hypertension-cg127. Published 2011. Accessed July 1, 2012.
21. Rudominer RL, Roman MJ, Devereux RB, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum. 2009;60(1):22-29.
22. Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia. 2005;48(10):1971-1979. (Pubitemid 41416905)
23. Yilmaz BA, Mete T, Dincer I, et al. Predictors of left ventricular hypertrophy in patients with chronic kidney disease. Ren Fail. 2007;29(3):303-307. (Pubitemid 46752345)
24. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41(2):218-223. (Pubitemid 36204892)
25. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L; CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82(5):1730-1736. (Pubitemid 20367976)
26. Vlahakos DV, Kosmas EN, Dimopoulou I, et al. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med. 1999;106(2):158-164. (Pubitemid 29115955)
27. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensinconverting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 1995;92(6):1387-1388.
28. Myerson SG, Montgomery HE, Whittingham M, et al. Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. Circulation. 2001;103(2):226-230. (Pubitemid 32095407)
29. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831-1838. (Pubitemid 37296092)
30. Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol. 2004;43(12):2200-2206. (Pubitemid 38757585)
31. Johnson DB, Foster RE, Barilla F, et al. Angiotensinconverting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction. 40% after acute myocardial infarction. J Am Coll Cardiol. 1997;29(1):49-54. (Pubitemid 27028719)
32. Delles C, Schmidt BM, Müller HJ, Oehmer S, Klingbeil AU, Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol. 2003;91(3):297-301. (Pubitemid 36143869)
33. Edelmann F, Tomaschitz A, Wachter R, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J. 2012;33(2):203-212.
34. Yoshida C, Goda A, Naito Y, et al. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. J Hypertens. 2011;29(2):357-363.
35. Stella P, Bigatti G, Tizzoni L, et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2004;43(2):265-270. (Pubitemid 38201154)
36. Sookoian S, Gianotti TF, Pirola CJ. Role of the C-344T aldosterone synthase gene variant in left ventricular mass and left ventricular structure-related phenotypes. Heart. 2008;94(7):903-910. (Pubitemid 351914703)
37. Lipworth BJ, McDevitt DG, Struthers AD. Hypokalemic and ECG sequelae of combined beta-agonist/diuretic therapy. Protection by conventional doses of spironolactone but not triamterene. Chest. 1990;98(4):811-815. (Pubitemid 20355482)